Ready to go slide decks that Chapter Leaders can use for their Spring or Fall Learning Series. Once a chapter has presented a slide deck, they may not present it again. To obtain the actual slide deck, contact Mariel.
Smoking Cessation: Counseling Strategies and Pharmacologic Treatments (1 CE)
- Participant will be able to identify current patterns of nicotine use and their health impacts.
- Participant will be able to discuss how to assess a patient for readiness to quit smoking and use the assessment to plan next steps toward cessation.
- Participant will be able to discuss treatment options available for smoking cessation, identifying those that have shown the most successful outcomes.
Effective Diagnosis and Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (1 CE)
- Describe epidemiology, pathophysiology and prevalence of ATTR, including hereditary and wild types
- Review current best practices in the effective diagnosis and management of ATTR-CM
- Describe barrier-reduction strategies to promote effective diagnosis and treatment of ATTR-CM
- Explain the use of shared decision-making strategies to assist patients with ATTR-CM and their families/caregivers in increased understanding of ATTR and the role of patient engagement in the process
- Discuss professional and patient education resources available for ATTR-CM.
Topics Coming Soon
- CV Risk Assessment Tools: how to translate results and recommendations to patients (FLS)
- Sleep disorders and their impact on CVD (FLS)
Peripheral Arterial Disease: Risk Factors, Screening & Treatment (1 CE)
- Outline the risk factors associated with PAD.
- Describe the clinical presentation of patients with PAD.
- List the steps to perform an Ankle Brachial Index (ABI) to screen for PAD.
- Discuss common treatments for PAD including a supervised exercise training (SET) program for patients with claudication.
National Guidelines for the Primary Prevention of CVD: Integrating Hypertension, Cholesterol, Diabetes, and Lifestyle Guidelines into Practice (1.5 CE)
- Cite and locate national guidelines related to CVD Risk Reduction
- Using a case study approach, apply current CVD prevention and risk reduction guidelines to patient care planning.
- Explain how CV risk assessment tools and patient-centered approaches can help to individualize risk factor management.
- Describe how to identify and manage CV risk factors according to current guideline recommendations.
Diabetes and the CV Nurse: A Stepwise Approach to Management (1.0 CE, 0.6 Pharma)
- Describe the association between diabetes and cardiovascular disease (CVD) and Chronic Kidney Disease (CKD).
- Review ADA standards of care and CVD and CKD risk reduction.
- Summarize clinical trial data supporting the use of antidiabetic therapy to improve CVD and CKD outcomes.
- Explain a multidisciplinary, team-based approach to management of the patient with Type 2 Diabetes and the role of the CV clinician.
Anti-hyperglycemic therapies: Improving CVD outcomes and hemoglobin A1c (1 CE)
- Describe the new challenge for cardiology in prescribing medications to manage diabetes as well as CVD
- Review recent clinical trials of anti-hyperglycemic therapies, CV out comes
- Discuss appropriate anti-hyperglycemic therapy selection, dose and potential side effects with new therapies
Review Case Studies as examples
Hypertension Guideline: Emphasis on Risk (1 CE)
- Review the new definition of hypertension and the categories of blood pressure in adults according to the new (2017) hypertension guidelines.
- Describe the association between high blood pressure and cardiovascular disease risk.
- List treatment strategies for hypertension according to patients level and risk, co-morbidities, race/ethnicity and age.
Lipid Management: Incorporating Recent Data into Clinical Practice (1 CE)
- Review current treatment guidelines for the management of dyslipidemia
- Analyze recent clinical outcomes trials of PCSK9 inhibitor therapies in patients with ASCVD, Familial Hyperlipidemia and Diabetes
- Discuss the relative value of PCSK9 inhibitor therapy considering costs and outcomes
- Review best practice strategies to insure patients have access to needed CVD therapies
Screening for Non-Valvular Atrial Fibrillation: Identifying the Undiagnosed Patient (1 CE)
- Review prevalence and common risk factors associated with non-valvular atrial fibrillation (NVAF).
- Describe typical signs and symptoms of NVAF and how to assess for them during a clinical encounter.
- Discuss the importance of pulse taking and follow up ECG to screen high risk patients for NVAF.
- Using case examples, illustrate how to initiate NVAF treatment, provide follow-up and collaboration across the continuum of care to ensure optimal patient outcomes.
Women’s Cardiovascular Care Across the Life Course – Promoting Prevention During Pregnancy and the Postpartum and Childbearing Years (1 CE)
- Identify three pregnancy complications associated with future cardiovascular or cardiometabolic risk
- Identify women who are at increased risk for developing these pregnancy-related complications
- Describe the cardiovascular or cardiometabolic risk associated with these pregnancy-related complications
- Describe clinical guidelines and recommendations for postpartum follow up and risk reduction in women with histories of these pregnancy-related complications
- Apply evidence-based interventions to promote healthy eating, physical activity, and breastfeeding during the postpartum and childbearing years
Antiplatelet Therapy Post Acute Coronary Syndrome: Choosing the Right Therapy for the Right Duration (1.0 CE, 0.7 Pharm)
- List guideline-recommended antiplatelet therapies and indications for their use in the post-ACS patient.
- Identify the most appropriate choice and duration of antiplatelet therapy in selected case studies.
- Outline strategies to improve patient understanding and adherence to long-term antiplatelet therapies.
Heart Failure Guideline Update: Medications, Diagnosis and Co-Morbidities (1.0 CE, 0.5 Pharm)
- Understand the recommendations of pharmacotherapies from the 2016 heart failure guideline update
- Identify the newest recommendations for initial and serial testing using biomarkers in patients with heart failure
- Change practice based on new information for patients with heart failure with preserved ejection fraction (HFpEF)
- Recognize guideline supported strategies for managing comorbidities in patients with HF, including hypertension, anemia and sleep apnea
Making the Link: Cardiometabolic Risk, Diabetes and Cardiovascular Disease (1.0 CE)
- Describe the relationship between cardiometabolic risk factors, diabetes and cardiovascular disease (CVD)
- Outline a cardiometabolic risk reduction plan for patients at risk for diabetes and cardiovascular disease
- Describe how accepted behavior change strategies can increase the rate of lifestyle and pharmacologic treatment adherence
Preventing and Managing VTE: Matching Patient Need to Optimal Therapy (1.0 CE, 0.5 Pharm)
- Identify prevalence rates of venous thromboembolism (VTE), including rates for morbidity and mortality
- Define professional guidelines for assessing risk in patients with VTE and discuss recommendations for patient management
- Describe methods and tools for ensuring effective communication with patients and caregivers as a means of improving adherence and self-care in patients with VTE
Strategies for Managing Dyslipidemia Patients with Residual CVD Risk (1.0 CE, 0.8 Pharm)
- Outline secondary prevention strategies in CVD patients with residual risk despite taking the maximum tolerated dose of statin therapy
- Describe the clinical steps taken to identify statin intolerance (statin-associated adverse effects)
- Differentiate between the indications for statins, PCSK9 inhibitors, and other LDL-lowering therapies
Diabetes and Cardiovascular Disease (CVD): Managing Patients with High Risk and Co-Morbid Conditions (1.0 CE, 0.5 Pharm)
- Summarize the treatment recommendations for patients with diabetes to reduce their risk of cardiovascular disease
- Describe the relationship between acute coronary syndrome (ACS) and hyperglycemia in patients with diabetes mellitus
- Describe how using shared decision-making with a complex patient can increase the rate of treatment adherence
Strategies for Managing Dyslipidemia Patients with Residual CVD Risk (1.0 CE, 0.8 Pharm)
- Outline secondary prevention strategies in CVD patients with residual risk despite taking the maximum tolerated dose of statin therapy.
- Describe the clinical steps taken to identify statin intolerance
- Differentiate between the indications for statins, PCSK9 inhibitors and other LDL-lowering therapies
- Identify the potential barriers to treatment adherence for patients requiring LDL-lowering therapies and solutions to address the barriers.
The Secondary Prevention Cocktail: The Key Ingredients (1.0 CE, 0.5 Pharm)
- Review the secondary prevention guidelines for the post-ACS patient.
Describe best practice recommendations for navigating the challenging hospital to home transition for the ACS patient
- List the specific strategies that have proven efficacy for patients at risk for non-adherence.
Heart Healthy Lifestyle Counseling: A Focus on the Female Patient (1.0 CE)
- Identify two pregnancy complications associated with future CVD risk
- Describe the integration of brief dietary counseling into a clinical visit
- Apply evidence-based interventions to promote physical activity and healthy eating including the PCNA Heart Healthy Toolbox.